中国特发性膜性肾病患者中抗THSD7A抗体研究
该研究在中国578例特发性膜性肾病患者中检测抗THSD7A抗体,发现2%阳性,其中PLA2R阴性患者中占16%。双阳性患者提示双重自身免疫反应,抗体水平与病情缓解或复发相关。
要点
- 中国特发性膜性肾病患者抗THSD7A抗体阳性率约2%。
- PLA2R阴性患者中抗THSD7A抗体阳性率约16%。
- 抗体清除与缓解相关,升高与复发相关。
核心结论
- THSD7A相关膜性肾病在中国患者中患病率低。
- 双阳性患者提示存在双重自身免疫反应。
研究设计与样本
- 研究纳入578例活检证实的特发性膜性肾病患者、114例继发性膜性肾病患者、64例疾病对照和20例健康对照。
- 采用免疫荧光法检测抗THSD7A抗体,免疫组化检测肾小球THSD7A抗原表达,并筛查抗PLA2R抗体及肾小球PLA2R表达。
主要发现
- 578例特发性膜性肾病患者中12例(2%)抗THSD7A抗体阳性,其中10例为单纯THSD7A阳性,占PLA2R阴性患者的16%(10/64)。
- 2例为抗THSD7A和抗PLA2R双阳性,肾小球中两种抗原共定位且表达增强。
- 114例继发性膜性肾病患者中,44例癌症患者中1例(2%)抗THSD7A抗体阳性,而抗PLA2R抗体阳性18例(41%)。
- 其他疾病对照和健康对照均未检测到抗THSD7A抗体。
- 随访中2例达到缓解的患者抗THSD7A抗体清除,1例复发患者抗体随蛋白尿增加而升高。
临床怎么用
- 对于PLA2R阴性的特发性膜性肾病患者,可考虑检测抗THSD7A抗体以明确病因。
- 抗THSD7A抗体水平可能用于监测疾病活动,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Thrombospondin type-I domain-containing 7A (THSD7A) was recently identified as the target antigen in about 10% of patients with M-type phospholipase A2 receptor (PLA2R)-negative membranous nephropathy in European and North American populations. The prevalence of THSD7A in other populations and their clinical associations deserve further clarification. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Immunofluorescence assay was performed to investigate anti-THSD7A antibodies in 578 consecutive patients with biopsy-proven idiopathic membranous nephropathy, 114 patients with secondary membranous nephropathy, 64 disease controls, and 20 healthy controls. Glomerular expression of THSD7A antigen was examined by immunohistochemistry. Anti-PLA2R antibodies and glomerular PLA2R expression were also screened. RESULTS: Among the 578 patients with idiopathic membranous nephropathy, 12 (2%) patients were identified as THSD7A-positive: ten patients were THSD7A-positive alone, which accounted for 16% (ten of 64) of PLA2R-negative patients; two patients were dual-positive for both anti-THSD7A and anti-PLA2R antibodies and showed enhanced expression of both antigens colocalized in glomeruli. Among the 114 patients with secondary membranous nephropathy, one among 44 (2%) patients with cancer had anti-THSD7A antibodies, whereas 18 of 44 (41%) had anti-PLA2R antibodies. No anti-THSD7A antibody was detected in other disease controls or healthy individuals. Clinical features were comparable between the patients with and without THSD7A. During follow-up, two patients who achieved remission had a clearance of circulating antibodies against THSD7A, whereas antibodies increased in parallel with proteinuria in a patient with a relapse. CONCLUSIONS: THSD7A-associated membranous nephropathy has a low prevalence in Chinese patients. The double-positive patients suggest dual autoimmune responses.
引用
- Wang J, Cui Z, Lu J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2017. PMID: 28801527. doi:10.2215/CJN.01460217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。